Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
ASP3082 (Setidegrasib) | KRAS G12D PROTAC Degrader | Selleck Chemicals
ASP3082 | KRAS G12D PROTAC | Probechem Biochemicals
Discovery of KRAS(G12D) selective degrader ASP3082 | Communications ...
RCSB PDB - 9L6F: Crystal structure of KRas G12D (GDP) in complex with ...
Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure ...
ASP3082 | 首个进入临床阶段的 KRAS G12D 降解剂（CAS No.: 2821793-99-9） - Book学术
ASP3082 in Patients With Solid Tumors and KRAS G12D Mutations - YouTube
【ASP3082】進行性固形がん / 第I相試験 / ASP3082 / KRAS G12D阻害剤 / EGFR阻害剤 | 国立がん研究 ...
Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo ...
ASP3082 for Tumors, Solid Clinical Trial 2022 | Power
ASP3082 mostra atividade antitumoral promissora e perfil de segurança ...
A Phase 1 Study of ASP3082 in Participants With Previously Treated ...
Phase I trial of ASP3082 in KRAS G12D-positive solid tumors - VJOncology
Raffaele Colombo: Efficacy and Safety of ASP3082 in NSCLC at Targets25 ...
ASP3082 for Cancer Clinical Trial 2025 | Power
ASP3082 for Solid Tumors Clinical Trial 2023 | Power
KRAS G12D inhibitor 7 | KRAS G12D 阻害剤 | MedChemExpress
Multiple Strategies to Develop Small Molecular KRAS Directly Bound ...
Setidegrasib (ASP-3082) | KRAS G12D PROTAC Degrader | MedChemExpress
全球首个！安斯泰来KRAS G12D降解剂在华申报临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
New Molecular Targets, Technologies, and Cancer Treatments | Blog | AACR
ESMO 2024 – Astellas defends its degrader | ApexOnco - Clinical Trials ...
KRAS Cancer ConnectsESMO24 abstract608O - Preliminary safety and ...
608O Preliminary safety and clinical activity of ASP3082, a first-in ...
MRTX1133和ASP3082（西妥昔单抗）KRAS G12D基因突变实体肿瘤新药-美联医邦
Frontiers | KRAS G12D targeted therapies for pancreatic cancer: Has the ...
ASP-3082, a PROTAC that selectively degrades KRAS G12D protein, shows ...
(ASP 3082)-药物靶点：KRAS G12D_在研适应症：实体瘤_专利_临床_研发
Abstract A070: Optimal efficacious dose prediction of a novel protein ...
ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable ...
KRAS G12D inhibitor 17 | TargetMol
化合物はそえるだけ - Azarashi_Pandaの日記
全球首个KRAS G12D蛋白降解药物ASP3082注射液在中国的临床试验申请获批,剑指多种实体瘤_全球肿瘤医生网
Trial in progress: A phase 1, first-in-human, open-label, multicenter ...
2023年，PROTACs进军肺癌的临床之年医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
KRAS G12D: The Next Frontier in Cancer Therapy | MedChemExpress
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs ...
驱动基因阳性晚期NSCLC治疗进展-MedSci.cn
RAS degraders: The new frontier for RAS-driven cancers: Molecular Therapy
KRAS G12D inhibitor 1 | | TargetMol
KRAS G12D抑制剂：GFH375、MRTX1133、HRS-4642、NT-112、ASP3082临床研究进展！ - 知乎
Setidegrasib, 2821793-99-9 | BroadPharm
新型KRAS抑制剂tricomplex或有望破解KRAS-G12C耐药难题 原文链接KRAS突变是人类癌症中最常见的致癌突变之一，其突变主要 ...
MRTX1133 | KRAS G12D inhibitor | CAS NO.:2621928-55-8 | GlpBio
The KRAS crowd targets its next cancer mutations
KRAS G12D変異陽性で既治療の進行固形癌にKRAS G12D分解誘導薬ASP3082は有望【ESMO 2024】：がんナビ
国内首款KRAS G12D蛋白降解剂新药ASP3082获批IND！
Setidegrasib(Setidegrasib) - 药物靶点：KRAS G12D_在研适应症：转移性胰腺癌，转移性胰腺腺癌，局部晚期非小 ...
速递｜2024 年最新 KRAS 临床药物进展 - 知乎
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
ASP3026 suppressed the growth of erythrocytic-stage parasites but not ...
KRAS G12D in situ mutation resistance model-II
An Update on Clinically Advanced PROTAC Degraders and Their Synthesis
ESMO 2024 preview – Astellas unveils its KRAS degrader | ApexOnco ...
KRAS G12D ligand-Linker Conjugate 2 | (KRAS) (G12D) Ligand-Linker ...
姜标点评 | 靶向KRAS，PROTAC来了_蛋白
